Lichinitser

Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg

A. Leo, G. Jerusalem, M. Martín, 2012 .

Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data

J. Body, S. Tjulandin, B. Bergström, 2006 .

Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase III trials

J. Body, S. Tjulandin, B. Bergström, 2006 .